论文部分内容阅读
重组人白细胞介素11(rhIL-11)为一种促血小板生长因子,临床资料显示,在淋巴瘤和其他实体瘤患者化疗过程中,应用 rhIL-11治疗可以有效地减轻血小板减少的程度和加速血小板恢复,从而减少患者对血小板输注的需求。但是,迄今为止,应用 rhIL-11治疗急性白血病诱导化疗后的血小板减少的临床报道较少。我们对国产注射用 IL-11用于急性白血病患者首次诱导化疗后血小板恢复的有效性和安全性进行了评估。
Recombinant human interleukin-11 (rhIL-11) is a platelet-derived growth factor, clinical data show that in patients with lymphoma and other solid tumors during chemotherapy, the application of rhIL-11 treatment can effectively reduce the degree of thrombocytopenia and acceleration Platelet recovery, thereby reducing the need for platelet transfusions in patients. However, to date, there have been few clinical reports of the use of rhIL-11 in thrombocytopenia after induction of chemotherapy for acute leukemia. We evaluated the efficacy and safety of a domestic injection of IL-11 for the first induction of platelet recovery after chemotherapy in patients with acute leukemia.